Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2025
Discovery & Translation

Science Spotlight: New insight into LAG3’s checkpoint function

BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Nov 8, 2022
Distillery Therapeutics

Silencing SOX2 target genes for glioblastoma

BioCentury | Oct 27, 2021
Distillery Therapeutics

SON identified as target in brain cancer

BioCentury | Aug 29, 2018
Translation in Brief

Accelerated healing

Why SOX2 and PITX1 could help treat chronic, non-healing wounds
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

BioCentury | Aug 29, 2018
Distillery Therapeutics

Dermatology

BioCentury | Apr 24, 2018
Distillery Techniques

Disease models

BioCentury | Aug 18, 2017
Emerging Company Profile

Teasing out Th1

EpiThany's strategy for creating more potent therapeutic cancer vaccines
Items per page:
1 - 10 of 55